NASDAQ · Biotechnology

INM (INM) Stock

$1.47 -2.00% NASDAQ: INM Healthcare

Valuation

MetricValue
Price$1.47
Market Cap$2.66M
P/E Ratio-0.18
P/B Ratio0.44
P/S Ratio0.67
EPS (TTM)$-8.36
52-Week High$5.50
52-Week Low$0.57
Dividend Yield0.00%

Financials & Margins

MetricValue
ROE-112.65%
ROA-54.61%
ROCE-44.44%
Gross Margin30.44%
Operating Margin-2.47%
Net Margin-2.46%
Debt/Equity0.06
Current Ratio6.00

Annual Financials (USD)

Metric20212022202320242025
Revenue$0$1.0M$4.0M$5.0M$5.0M
Operating Profit$-12.0M$-14.0M$-8.0M$-8.0M$-8.0M
Net Profit$-13.0M$-19.0M$-8.0M$-8.0M$-8.0M
EPS$-938.91$-16582.00$-64.92$-20.14$-8.36
Op Margin—-1266.0%-202.6%-176.9%-160.2%

Balance Sheet (USD)

Metric20212022202320242025
Total Assets$12.0M$16.0M$19.0M$16.0M$21.0M
Total Liabilities$3.0M$5.0M$3.0M$4.0M$3.0M
Cash$9.0M$8.0M$12.0M$9.0M$15.0M
Borrowings$0$1.0M$1.0M$1.0M$1.0M

Latest News

Mentari Therapeutics Announces $200 Million Private Placement for Migraine Prevention Pipeline PR Newswire · Jul 22, 2026 InMed Pharmaceuticals Amends Deal With Mentari Therapeutics MT Newswires · Jul 7, 2026 InMed Pharmaceuticals and Mentari Therapeutics Announce Amendment to Merger Agreement and Filing of Registration Statement on Form S-4 TMX Newsfile · Jul 6, 2026 InMed Pharmaceuticals Regains Compliance with Nasdaq Continued Listing Requirements TMX Newsfile · Jun 4, 2026 /C O R R E C T I O N -- InMed Pharmaceuticals/ PR Newswire · May 20, 2026

Cash Flow (USD)

Metric20212022202320242025
Operating Cash Flow$-10.0M$-16.0M$-7.0M$-7.0M$-8.0M
Investing Cash Flow$0$-1.0M$-1.0M$0$0
Financing Cash Flow$-2.0M$-2.0M$0$-1.0M$4.0M
Net Cash Flow$2.0M$-1.0M$3.0M$-2.0M$5.0M
Free Cash Flow$-10.0M$-16.0M$-7.0M$-7.0M$-8.0M

Valuation & Return Ratios

MetricValue
PEG Ratio—
EV / EBITDA-0.03
FCF Yield-332.86%
Quick Ratio3.11
Interest Coverage—
Return 1Y-42.81%
Return 3Y-91.72%
Return 5Y-99.88%

Ownership

Insiders Held0.12%
Institutions Held70.72%
Institutions Float Held70.81%
Institutional HolderSharesReport Date
Sabby Management, LLC220,2602026-03-31
Citadel Advisors Llc46,9732026-03-31
Virtu Financial LLC19,9802026-03-31
Two Sigma Securities, LLC18,7182026-03-31
UBS Group AG8,0682026-03-31

Peer Comparison

TickerPriceChangeP/EMarket CapDiv Yield
BDRXBiodexa Pharmaceuticals Plc $1.71 -3.39% 0.00 $1.28M 0.00%
BIVI $1.52 +6.29% -0.11 $11.46M 0.00%
CNSP $5.40 +0.75% -0.14 $3.10M 0.00%
ESLAEstrella Immunopharma, Inc. $0.78 +0.06% -2.25 $33.59M 0.00%
GLMD $0.62 +3.67% -0.25 $5.13M 0.00%

About INM

INM is led by CEO Eric A. Adams Chem., publicly traded since 2014.

INM stock trades at $1.47 with a market capitalization of $2.66M. The stock is valued at a price-to-earnings (P/E) ratio of -0.18, price-to-book of 0.44, price-to-sales of 0.67. Over the past 52 weeks the stock has ranged between $0.57 and $5.50, and currently trades 73.3% below its 52-week high.

On profitability, INM generates a return on equity (ROE) of -112.65%, return on capital employed of -44.44%, an operating margin of -2.47%, a net profit margin of -2.46%.

Related Healthcare Stocks

LLY Drug Manufacturers - General $1185.71 -0.52% JNJ Drug Manufacturers - General $259.24 +0.88% ABBV Drug Manufacturers - General $246.04 +0.89% UNH Medical - Healthcare Plans $407.08 +0.77% MRK Drug Manufacturers - General $128.57 +0.16% NVS Drug Manufacturers - General $158.83 -0.64% NVO Biotechnology $51.58 +1.22% TMO Medical - Diagnostics & Research $594.00 +2.41% AMGN Drug Manufacturers - General $387.64 -1.39% ABT Medical - Devices $108.03 +0.70% GILD Drug Manufacturers - General $132.73 -1.18% PFE Drug Manufacturers - General $26.74 +2.06%

Popular Stocks

Apple (AAPL)Microsoft (MSFT)NVIDIA (NVDA)Alphabet (GOOGL)Amazon (AMZN)Meta (META)Tesla (TSLA)Broadcom (AVGO)JPMorgan (JPM)Visa (V)

Screens featuring this stock

High ROE Healthcare StocksLow P/E Healthcare StocksHigh Net Margin Healthcare StocksDividend Healthcare StocksLow Debt Healthcare StocksNasdaq High ROE StocksAll stock screens
Run Stock Screener Investing Guides